At a glance
ClinicalIndex Comparison RecordN/ACompleted· 42 enrolled
Drug / intervention
palbociclib plus letrozoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective, Multicenter, Observational Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
In Brief
An observational study evaluating palbociclib plus letrozole for Breast Cancer. Completed, enrolled 42 participants across 13 sites.
Detailed Summary
This is a retrospective, multicenter, observational study in Japan. The primary objective is to evaluate overall survival (OS) in Japanese patients with HR+/HER2- advanced breast cancer who have been treated with palbociclib plus letrozole. This observational study was planned as follow-up study of Japanese phase 2 study of palbociclib (NCT01684215, phase 2 portion of A5481010 study).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartFeb 2021
Primary CompletionSep 2023
TodayJul 2026
First PostedFeb 3, 2021
Enrollment StartFeb 3, 2021
Primary CompletionSep 29, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.4 years ago
Interventions
palbociclib plus letrozoledrug
palbociclib plus letrozole